What’s Instore For Big Pharma In 2017?Rupert Hargreaves
What's Instore For Big Pharma In 2017?
The US pharmaceutical industry has had a tough 2016, and according to Morgan Stanley, the outlook for the sector is no better next year.
Indeed, according to a lengthy report on the state of the pharmaceutical industry from Morgan, there are few catalysts for the sector’s growth next year and thanks to this the industry will be at the mercy of political decisions.
- Valeant Pharmaceuticals Intl Inc Downgraded After Ackman Cuts Stake
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible